ArticleJournal of gynecologic oncology2026
Risk stratification of groin node metastases in vulvar cancer biopsies based on histology and immunohistochemical staining.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn vulvar squamous cell carcinoma (VSCC), the presence or absence of groin lymph node metastases (LNM) is relevant for choice of treatment and outcome. Risk stratification at time of primary diagnosis could impact choice of treatment, especially since VSCC often affects elderly patients with increased surgical risks. This study evaluates the prognostic value of histopathological features and immunohistochemical (IHC) markers (p16, p53, L1CAM, and PD-L1) for predicting groin LNM in primary biopsy specimens.
methodsA retrospective cohort study was conducted, including patients with macroinvasive VSCC (depth of invasion >1mm) undergoing primary surgery between 2005 and 2015. Pathological revision of both the primary biopsy and definitive resection was performed. IHC staining with p16, p53, L1CAM, and PD-L1 was applied to all biopsies. The primary outcome was the risk of groin LNM at primary diagnosis.
resultsA total of 118 patients were included, of whom 34.7% (n=41) had groin LNM. In resected specimens, groin LNM correlated significantly with depth of invasion ≥4mm (p=0.002), poor differentiation (p=0.002), invasive or spray-patterned growth (p=0.024), and lymphovascular space invasion (LVSI) (p<0.001). In biopsy samples, poor differentiation (p=0.039) and invasive/spray-patterned growth (p=0.044) were associated with higher groin LNM risk. IHC markers did not demonstrate significant predictive value.
conclusionThese findings suggest that poor differentiation and invasive/spray-patterned growth in biopsies are indicative of increased groin LNM risk, whereas well-differentiated tumors and pushing growth patterns may confer a more favourable prognosis. Further research is warranted to optimize surgical decision-making regarding groin node management. IHC markers evaluated herein showed no significant prognostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.